Researchers from Sinopharm and its local partners in the Middle East say the trial involved around 40,380 participants with the company s two vaccines one developed by the Wuhan Institute of Biological Products and the other by the Beijing Institute of Biological Products and a placebo. The trial was carried out in four countries Bahrain, the United Arab Emirates, Egypt and Jordan. However, the study provided data for just Bahrain and the UAE. There s nothing very surprising. It s consistent with what they have claimed previously, but it does not completely eliminate the doubts about Sinopharm, said Jin Dong-yan, a medical professor at the University of Hong Kong who was not involved with the study.
Two vaccines made by China s Sinopharm appear safe and effective against COVID-19, according to a study published in a medical journal. Scientists had been waiting for more details about the two vaccines, even though they already are being used in many countries, and one recently won the backing of the World Health Organisation for emergency use. The report, published online in the Journal of the American Medical Association, concluded the two vaccines are about 73 per cent and 78 per cent effective, as Sinopharm has previously claimed. Researchers from Sinopharm and its local partners in the Middle East say the trial involved around 40,380 participants with the company s two vaccines one developed by the Wuhan Institute of Biological Products and the other by the Beijing Institute of Biological Products and a placebo.
A study found that two Sinopharm vaccines are 73% and 78% effective against COVID-19, which aligns with previous reports from the company. Some still have doubts about the effectiveness of the